YI111 Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Jun L. Liu

Location

N/A, N/A

Exchange

Nasdaq

Website

https://111.com.cn

Summary

111, Inc.

Company Info

CEO

Jun L. Liu

Location

N/A, N/A

Exchange

Nasdaq

Website

https://111.com.cn

Summary

111, Inc.

AI Insights for YI
5 min read

Quick Summary

111 Inc, ticker YI, is a China-based healthcare commerce company operating an integrated online and offline platform. The company sells medical, pharmaceutical, and wellness products through online retail channels, wholesale distribution, and offline pharmacy locations. Its customers include individual consumers seeking medicines and health products, retail pharmacies that buy through its wholesale network, and healthcare-related businesses that need drug supply and fulfillment services. The company has historically operated offline retail pharmacies under the Yi Hao Pharmacy brand in cities such as Guangzhou, Wuhan, Tianjin, and Kunshan. YI is listed on Nasdaq as a depositary receipt and operates in the retail industry within China’s healthcare market.

Strengths

•

YI’s main strength is its integrated online and offline healthcare retail model, which gives it exposure to multiple customer channels.

•

The company has a sizable revenue base, indicating that it has already built meaningful commercial scale in China’s healthcare products market.

•

Its platform approach may help connect consumers, pharmacies, suppliers, and fulfillment infrastructure more efficiently than a purely local pharmacy model.

•

The company also operates in a structurally important sector because demand for medicines, wellness products, and pharmacy access is tied to long-term healthcare consumption.

•

Its beta of 0.667 suggests that the stock may be less sensitive to broad market movements than some higher-beta equities, although individual volatility can still be high.

Key Risks

•

YI faces regulatory risk because pharmacy retail, drug distribution, online healthcare services, and cross-border capital markets are heavily regulated.

•

Any changes in Chinese healthcare pricing rules, online pharmacy regulations, or pharmaceutical distribution standards could affect revenue and margins.

•

The company also faces intense competition from larger platforms and local pharmacy networks, which may limit pricing power.

•

Continued losses could raise concerns about cash generation, financing needs, and the sustainability of the business model.

What to Watch

For the most recent reported quarter, the available data points to continued large-scale revenue generation but weak profitability.
YI reported total revenue and operating revenue of about 1.80 billion, showing that the company still has meaningful commercial activity in China’s healthcare retail and distribution market.
Gross profit was positive at about 103.45 million, but the company still reported negative net income of about 3.22 million and negative EPS of -0.0543.
Operating income was close to break-even but still negative, which suggests that cost control may be improving but profitability has not yet been firmly established.
No specific new product launch, acquisition, partnership, or management change for YI was identified in the provided recent news set.
The supplied news items were mostly about Binance, broader Chinese consumer and technology companies, and unrelated market stories rather than company-specific events for 111 Inc.

Price Drivers

•

YI’s stock price is likely driven primarily by revenue growth, profitability progress, liquidity, and investor confidence in China’s online healthcare market.

•

The company reported operating revenue of about 1.80 billion and total gross profit of about 103.45 million, but it also showed negative EPS and a net loss, which can weigh on valuation.

•

Investors may focus on whether the company can improve gross margins, reduce operating losses, and move toward consistent net profitability.

•

The stock’s valuation may also be affected by China macro sentiment, regulatory developments in healthcare and internet platforms, and U.S.-listed Chinese depositary receipt risk.

•

Trading liquidity is another factor because recent volume appears relatively low, and low-volume stocks can experience larger price swings.

•

The 52-week range from 2.48 to 11.17 indicates substantial volatility and suggests that sentiment, earnings surprises, or changes in risk appetite can move the stock sharply.

Recent News

•

The provided recent news feed does not include clear company-specific news about 111 Inc or ticker YI.

•

Several items mention Yi He, the Binance co-founder, but those stories are unrelated to 111 Inc despite the similar name.

•

Other supplied articles discuss Binance licensing, memecoins, Mixue’s Hong Kong IPO, Netflix, Enbridge, dividend stocks, Alibaba-related AI developments, and Greenshoe funding.

•

These stories may provide broad context about China, technology, consumer markets, or market sentiment, but they should not be treated as direct developments for YI.

•

Based on the supplied news, there were no reported YI partnerships, acquisitions, product launches, controversies, or management changes.

•

Investors would likely need to rely on company filings, earnings releases, and official announcements for recent company-specific updates.

Market Trends

•

YI is affected by the long-term trend toward online healthcare purchasing and digital pharmacy infrastructure in China.

•

Consumers increasingly expect convenient ordering, broad product selection, delivery, and trusted medicine sourcing, which supports online pharmacy models.

•

At the same time, competition in Chinese internet retail remains intense, and large platforms can use scale, logistics, and traffic advantages to pressure smaller companies.

•

Healthcare retail demand may be more resilient than discretionary consumer categories, but margins can still be constrained by regulation, procurement practices, and price competition.

•

Broader sentiment toward Chinese equities and U.S.-listed Chinese depositary receipts can strongly affect valuation regardless of company execution.

•

Investors are also increasingly focused on profitability and cash flow, so revenue growth alone may not be enough to support the stock without evidence of margin improvement.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on YI

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show